Advertisement

Topics

Karolinska Development AB Umecrine Cognition Appoints Dr. To Its Board Of Directors

20:00 EDT 4 Sep 2017 | BioSpace

STOCKHOLM - September 5, 2017. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company in clinical development with a novel GABAA receptor modulator for the treatment of hepatic encephalopathy (HE) in patients with liver disease, today announces that Dr. Thomas P. Blackburn has been appointed as a new member of...

Original Article: Karolinska Development AB Umecrine Cognition Appoints Dr. To Its Board Of Directors

NEXT ARTICLE

More From BioPortfolio on "Karolinska Development AB Umecrine Cognition Appoints Dr. To Its Board Of Directors"

Quick Search
Advertisement
 

Relevant Topic

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...